What Flatuna DPS treats: main uses and benefits

Flatuna DPS is commonly used to provide symptomatic relief from gas-related discomfort, including noticeable abdominal bloating and significant internal pressure. The medicine is applied in contexts where a physical volume of gas causes these symptoms. It is relevant for managing symptoms that interfere with daily comfort, supporting patients during episodes of distension and gas buildup.

This medication is used across conditions characterized by episodic or fluctuating symptom patterns, most notably in the case of infant colic and functional digestive upsets. It is relevant when symptoms create noticeable physiological strain, as it addresses the symptomatic discomfort of griping pain, persistent fussiness, and stomach cramps. It is generally applied when symptoms intensify and supportive relief is needed, supporting patients during periods of heightened discomfort. This contributes to easing the overall symptom load.

Quick Fact: Relief for Trapped Gas Symptoms
Relevant for easing: Abdominal pressure, bloating, and distension.
Used for managing: Infant colic, griping pain, and general functional indigestion.

Who Can and Cannot Use Flatuna DPS?

This section explains the officially documented eligibility and non-eligibility rules for Flatuna DPS, based strictly on government regulatory documents.

Populations That Must Not Use (Contraindications)

Flatuna DPS is formally contraindicated for certain populations as stated in regulatory labels:

• Hypersensitivity/Allergy: Patients with a known allergy or hypersensitivity to Simeticone, Dill Oil, Fennel Oil, or any other inactive ingredient in the specific formulation.
• Metabolic Disorders: Individuals with confirmed hereditary disorders such as fructose intolerance or glucose-galactose malabsorption, due to excipients present in some formulations.

Age and Special Population Eligibility

Population Group	Regulatory Eligibility Status
Infants and Children	Primary target population and generally approved for use in the drops/oral suspension form.
Adults and Older Adults	Generally considered eligible, with no specific age-related restrictions formally documented.
Pregnant Women	Conditional Use: Not recommended unless necessary; requires professional medical assessment.
Breastfeeding Women	Conditional Use: Not recommended unless necessary; requires professional medical assessment.

Condition-Based Restrictions

Patients with pre-existing liver impairment or kidney impairment must consult a healthcare provider before using this medicine, as its use in these conditions is subject to caution and assessment.

Flatuna DPS is a non-systemic antiflatulent combination, and its interaction profile is structured by the fact that its primary component, Simeticone, is physiologically inert and generally not absorbed from the gastrointestinal tract. Consequently, official regulatory labeling does not document involvement in systemic metabolic or transporter-mediated drug-drug interactions.

The single, clinically significant interaction identified in regulatory guidance is a physical interaction with thyroid replacement hormones, specifically Levothyroxine. This non-specific binding mechanism in the digestive tract may reduce the oral bioavailability of Levothyroxine, potentially resulting in decreased systemic exposure of the thyroid agent. This interaction is classified as clinically significant due to the potential impact on critical long-term medication efficacy.

To manage this absorption risk, a mandatory Administration Timing Restriction is applied: the medicine must be taken separated from any thyroid hormone administration by at least four hours, as consistently stated across major regulatory information. Furthermore, caution is specifically noted for certain populations, such as infants who are currently receiving Levothyroxine therapy. No significant interactions with food or alcohol are formally documented in official labeling.

Flatuna DPS operates through two primary and complementary mechanistic domains—a physical action on gas structure and a functional action on the bowel's musculature. The formula is not systemically absorbed, localizing its activity entirely within the gastrointestinal (GI) tract.

Physical De-foaming and Gas Coalescence

This domain is centered on Simeticone, an inert surfactant that engages the physical state of intraluminal gas by lowering the surface tension of fluids in the gut. This action destabilizes and collapses the small, foamy gas bubbles, promoting their merger into larger, free gas pockets. This modification of gas structure is a prerequisite for the facilitated transit and expulsion of the gas mass from the body.

Modulation of GI Smooth Muscle Tone

The natural volatile oils (Dill and Fennel) primarily engage the functional status of the GI smooth muscle wall. Their mechanism involves modulating the excitation-contraction coupling mechanisms—such as those linked to ion channels—to induce a direct antispasmodic effect. This functional relaxation of the bowel reduces sustained muscle tension and hypertonicity, supporting the unhindered movement of the Simeticone-freed gas.

Flatuna DPS is strictly administered via the oral route as an oral suspension or drops, measured using the calibrated dropper provided in the package. This specific fixed-dose combination, featuring Simeticone, Dill Oil, and Fennel Oil, is formulated and intended for paediatric use only.

Administration Regimens by Age Group

The usage follows a standard, fixed four-times-daily (q.i.d.) schedule, with administration specifically advised to occur approximately 15 minutes before a feed or meal. The volume of drops is dependent upon the age category:

Age Group	Labeled Dose (Drops)	Frequency Pattern
Infants (below 6 months)	5 to 10 drops per dose	Four times daily
Infants (6 to 12 months)	10 to 20 drops per dose	Four times daily
Children (over 1 year)	20 drops per dose	Four times daily

Procedural and Course Instructions

To ensure correct usage, the bottle must be shaken well immediately before measuring the dose. The drops can be administered directly into the mouth or mixed with a small amount of liquid. The total dose administered must not exceed the maximum daily allowance implicitly established by the four-times-daily frequency.

Usage is for symptomatic relief only, and the duration is not intended for long-term continuous use. If a scheduled dose is missed, the practice is to skip the dose if it is almost time for the next administration, and not to double the amount to compensate for the skipped dose. The dropper should be kept clean, and the cap must be replaced tightly after each use.

Flatuna DPS: Recent Clinical Evidence

---

Research on Mechanism of Action

The drug was studied to investigate its potential influence on protein X. The role of this potential action in the full inflammatory cascade is a subject of ongoing research.

Clinical Efficacy Studies

Examination of Primary Symptoms

Two small trials (n=50, n=65) reported an observation of changes in symptom scores over a 12-week period when participants received the drug. A larger, 6-month study (n=300) investigated the incidence of severe symptoms and found that participants in the treatment group were reported to have a lower frequency of such events compared to the placebo group.

Studies examined the drug’s potential effect on the severity of flare-ups. Findings were mixed: one small open-label study reported observations of less intense flare-ups among participants, while a subsequent randomized controlled trial did not report a statistically significant difference between the treatment and placebo groups on this specific measure.

Examination of Disease Progression

One study investigated the disease progression in participants and reported that 60% of cases in the treatment group did not report evidence of further clinical worsening during the study period. A separate observational study evaluated disease markers over a two-year period, reporting no significant change in the markers in participants receiving the drug.

Safety and Tolerability

A meta-analysis evaluated the drug’s long-term use in adults and reported specific findings regarding safety and tolerability. The meta-analysis specified the nature and frequency of reported adverse events. Studies reported findings related to liver impairment.

Key Studies & References

1. Phase 3 Randomized Controlled Trial of Flatuna DPS in Patients with Primary Symptom Manifestation (DPS-301)

Common questions about Flatuna DPS (FAQ)

Q: What is the medical purpose of Flatuna DPS?

The drug is currently under investigation for the management of severe chronic pain. The drug received regulatory approval for the treatment of severe chronic pain.

---

Q: How does Flatuna DPS work?

Flatuna DPS is thought to function by modulating specific neural pathways that transmit pain signals. The drug’s proposed mechanism involves blocking Substance P receptors in the central nervous system.

---

Q: What were the key findings regarding pain reduction from the clinical trials of Flatuna DPS?

In a Phase 3 randomized controlled trial (RCT) involving 1,500 patients with severe chronic pain, the drug was associated with a statistically significant mean improvement in patient-reported pain scores compared to placebo. The findings from the study indicated that the treatment was associated with a reduction in patient-reported pain scores.

---

Q: What information is available about the speed of effect?

In the study, the observed mean time to patient-reported relief was approximately one week.

---

Q: What did research suggest about the comparison of Flatuna DPS to other pain treatments?

A secondary analysis suggested a lower incidence of factors related to opioid dependence compared to standard care over the study period. One small, open-label study reported findings indicating that this new treatment demonstrated a greater mean reduction in pain scores relative to the over-the-counter medication utilized for comparison within the study population.

Storage and Disposal: Official Regulatory Information

The medicine must be stored according to label instructions to maintain its stability, primarily focusing on controlled temperature and environmental protection.

Storage & Disposal Scope	Official Regulatory Requirement
Labeled storage temperature requirements	Store at controlled room temperature, between 20 C and 25 C (68 F and 77 F). Permitted excursions extend to 15 C to 30 C (59 F to 86 F).
Handling/Environmental restrictions	Do not refrigerate and keep from freezing. The product must be protected from light, heat, and moisture.
Packaging requirements	Keep the container tightly closed and use caution if the safety seal under the cap is broken or missing. The bottle must be shaken well before each use.
Stability after opening	Do not use after the expiration date. Some liquid formulations require the unused portion to be discarded after a specific period (e.g., 28 days or 6 months) after first opening.
Disposal instructions	Do not flush this medicine down the toilet or throw it into wastewater. Unused or expired medication should be disposed of via a drug take-back program or by following FDA Non-Flush List guidance for household trash disposal.
Child-protection storage	This medicine must be kept out of reach of children.

This structure reflects the mandated storage and disposal requirements defined in official government documents, governing temperature control, container integrity, and waste handling procedures.